We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breakthrough Method to Enable Early Risk Stratification of Deadly Blood Cancer

By LabMedica International staff writers
Posted on 04 Dec 2024

Multiple myeloma is an incurable blood cancer, with patients typically surviving an average of eight years after diagnosis. More...

Those with smoldering multiple myeloma experience no symptoms until the disease advances to multiple myeloma. However, there is currently no reliable method in clinical settings to predict which patients will progress to multiple myeloma. Now, new research has demonstrated a novel technique that can accurately predict the likelihood that a patient with smoldering multiple myeloma will develop full-blown multiple myeloma.

In a groundbreaking study, researchers at the University of Manitoba (Winnipeg, Canada) utilized three-dimensional (3D) imaging and microscopy to examine genetic material within a patient's cells, revealing genomic changes and instability. By focusing on the telomeres, the protective ends of chromosomes, the 3D measurement tools developed by the team could determine whether a cell is stable or cancerous, even before symptoms emerge.

To achieve these pioneering results, the researchers employed single-cell nuclear imaging using 3D analysis. They also applied super-resolution imaging to observe cancer-related DNA and the genomic structure at a nanometer scale. This advanced technology holds promise not only for identifying smoldering multiple myeloma progression but also for detecting other types of cancer. The findings, co-published in the American Journal of Hematology, build on previous research identifying thyroid cancer histotypes published last year.

“This breakthrough allows us to risk-stratify smoldering multiple myeloma to identify the subgroup with high risk of progression, which allows for tailored treatments of this risk group,” said Dr. Sabine Mai, UM Canada Research Chair in genomic instability and nuclear architecture in cancer, who led the research team. “Equally important, the published assay [lab procedure] allows us to monitor the larger subgroup of patients with stable smoldering multiple myeloma.”

If we apply the right treatments early enough, the outcome will be the increased progression-free survival of patients — and potentially someday, a cure for myeloma,” added Dr. Mai.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pipette
Accumax Smart Series
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The VeraBIND Tau assay is a novel blood test that identifies the presence of active tau pathology (Photo courtesy of 123RF)

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals

Alzheimer’s disease (AD), the sixth leading cause of death in the United States, affects an estimated 7.2 million Americans aged 65 or older. Current diagnostic methods for AD are often invasive, expensive,... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.